Article

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Debra Patt, MD, PhD, MBA, MPH
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Mikkael Sekeres, MD
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Gladys Antelo-Allen
Mikkael Sekeres, MD
Clayton Irvine, PharmD, MBA, MS.
Debra Patt, MD, PhD, MBA, MPH
Carrie Kozlowski, OT, MBA, Upfront Healthcare
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo